NME Blockbuster Approvals — September 16, 2026

Scholar Rock Inc received FDA NME approval for APITEGROMAB-MSTN (ISEMBYLD) with Priority Review and Orphan Drug designations, indicating significant unmet need and potential for premium pricing in a rare disease market.

Telix Pharmaceuticals US Inc received FDA NME approval for FLORETYROSINE F 18 (PIXCLARA) with Priority Review and Orphan Drug designations, positioning it as a novel diagnostic or therapeutic agent in a specialized orphan indication.

Both APITEGROMAB-MSTN and FLORETYROSINE F 18 face potential competition from existing or pipeline therapies in their respective orphan indications, though specific competitors are not disclosed.

Pricing power for both drugs is undisclosed; however, Orphan Drug status typically supports premium pricing, though payer pushback or IRA negotiation could limit commercial upside.

APITEGROMAB-MSTN (ISEMBYLD) from Scholar Rock Inc represents a new therapeutic option in a rare disease, with potential for rapid adoption given Priority Review and Orphan Drug designations.

FLORETYROSINE F 18 (PIXCLARA) from Telix Pharmaceuticals US Inc offers a novel diagnostic or therapeutic tool in an orphan setting, with potential for strong adoption if it addresses an unmet need.

Both approvals in this period are NMEs with Orphan Drug and Priority Review designations, highlighting FDA's continued focus on expediting therapies for rare diseases with high unmet need.

{"entity" => "APITEGROMAB-MSTN (ISEMBYLD) - Scholar Rock Inc", "reason" => "Newly approved NME with undisclosed commercial details; launch execution and payer coverage will be critical for revenue generation.", "trigger" => "Launch date announcement and initial sales data"}

{"entity" => "FLORETYROSINE F 18 (PIXCLARA) - Telix Pharmaceuticals US Inc", "reason" => "Newly approved NME with undisclosed commercial details; market adoption and competitive positioning need monitoring.", "trigger" => "Launch date announcement and initial sales data"}